摘要
目的评价逍遥散联合用药的临床疗效及其安全性。方法整群选取2012年1月—2014年10月门诊和住院56例双相抑郁症患者随机分为两组,对照组28例给予阿米替林,观察组28例在对照组的基础上给予逍遥散,比较两组患者的临床疗效,分析逍遥散作用靶点;并分别于治疗前和治疗第2、4周进行HAMD、TESS量表评分。结果治疗2周后,观察组的临床有效率显著高于对照组(71.4%VS 42.8%,χ2=4.667,P=0.029);治疗4周痊愈率差异有统计学意义(82.1%VS 53.5%,χ2=5.240,P=0.02);观察组HAMD治疗4周后得分均显著低于对照(11.12±3.52)VS(15.70±2.25)(t=5.841,P=0.001);治疗后两组各项TESS因子指标均有显著下降,两组之间差异具有统计学意义(P<0.01或P<0.001)。结论逍遥散联合阿米替林治疗双向抑郁症临床安全有效,值得推广。
Objective To evaluate Xiaoyaosan and safety of combination therapy. Methods From January 2014 to October 2012,56 patients with bipolar depression were randomly divided into two groups, 28 patients in control group received amitriptyline,28 patients in observation group were given Xiaoyaosan on the basis of the control group, the two groups were compared clinical efficacy analysis Xiaoyaosan targets; respectively before treatment and at 2, 4 weeks HAMD, TESS scores,while fasting venous blood drawn to Western blot serum of patients with 5 each-HT1 A and 5-HT2 A receptor protein content. Results After 2 weeks of treatment, clinical observation group was significantly higher efficiency（71.4% VS 42.8%, χ^2=4.667,P= 0.029）; presence of four weeks treatment cure rate significantly different（82.1% VS 53.5%, χ^2=5.240,P =0.02）; observed after 4 weeks of treatment group HAMD scores were significantly lower than the control（11.12±3.52）VS（15.70±2.25）,（t=5.841,P=0.001）.Conclusion The treatment of bipolar depression clinical safety and effectiveness of Xiaoyao Powder Combined with amitriptyline, worthy of promotion.
出处
《中外医疗》
2015年第22期112-113,116,共3页
China & Foreign Medical Treatment
